$0.86
2.33%
Downside
Day's Volatility :11.57%
Upside
9.46%
18.02%
Downside
52 Weeks Volatility :72.88%
Upside
66.92%
Period | Dariohealth Corp | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -5.36% | -2.6% | 0.0% |
6 Months | -50.57% | 2.6% | 0.0% |
1 Year | -16.83% | 15.9% | 0.0% |
3 Years | -94.82% | 10.0% | -26.7% |
Market Capitalization | 27.9M |
Book Value | $1.87 |
Earnings Per Share (EPS) | -1.14 |
PEG Ratio | 0.0 |
Wall Street Target Price | 3.83 |
Profit Margin | -205.62% |
Operating Margin TTM | -162.06% |
Return On Assets TTM | -34.74% |
Return On Equity TTM | -74.91% |
Revenue TTM | 23.1M |
Revenue Per Share TTM | 0.63 |
Quarterly Revenue Growth YOY | 111.00000000000001% |
Gross Profit TTM | 14.0M |
EBITDA | -53.6M |
Diluted Eps TTM | -1.14 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.03 |
EPS Estimate Next Year | -0.8 |
EPS Estimate Current Quarter | -0.27 |
EPS Estimate Next Quarter | -0.24 |
What analysts predicted
Upside of 345.35%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 7.4M | ↑ 43.02% |
Net Income | -17.8M | ↑ 13.09% |
Net Profit Margin | -240.78% | ↑ 63.73% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 7.6M | ↑ 2.23% |
Net Income | -17.8M | ↓ 0.2% |
Net Profit Margin | -235.04% | ↑ 5.74% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 7.6M | ↑ 0.22% |
Net Income | -29.0M | ↑ 63.15% |
Net Profit Margin | -382.62% | ↓ 147.58% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 20.5M | ↑ 170.76% |
Net Income | -76.8M | ↑ 164.81% |
Net Profit Margin | -374.21% | ↑ 8.41% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 27.7M | ↑ 34.82% |
Net Income | -62.2M | ↓ 18.98% |
Net Profit Margin | -224.88% | ↑ 149.33% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 20.4M | ↓ 26.41% |
Net Income | -54.9M | ↓ 11.79% |
Net Profit Margin | -269.56% | ↓ 44.68% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 6.2M | ↓ 12.94% |
Net Income | -16.6M | ↓ 233.66% |
Net Profit Margin | -269.59% | ↓ 445.19% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 3.5M | ↓ 42.82% |
Net Income | 16.9M | ↓ 201.92% |
Net Profit Margin | 480.5% | ↑ 750.09% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 3.6M | ↑ 2.79% |
Net Income | -12.0M | ↓ 170.99% |
Net Profit Margin | -331.88% | ↓ 812.38% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 5.8M | ↑ 59.24% |
Net Income | -6.9M | ↓ 42.36% |
Net Profit Margin | -120.13% | ↑ 211.75% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 6.3M | ↑ 8.63% |
Net Income | -3.4M | ↓ 51.3% |
Net Profit Margin | -53.86% | ↑ 66.27% |
Q3 FY24 | Q/Q Change | |
---|---|---|
Revenue | 7.4M | ↑ 18.67% |
Net Income | 14.6M | ↓ 533.61% |
Net Profit Margin | 196.79% | ↑ 250.65% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 14.1M | ↑ 102.52% |
Total Liabilities | 5.2M | ↑ 71.22% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 24.6M | ↑ 74.38% |
Total Liabilities | 5.7M | ↑ 9.9% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 35.4M | ↑ 44.11% |
Total Liabilities | 7.3M | ↑ 27.86% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 100.8M | ↑ 184.61% |
Total Liabilities | 15.2M | ↑ 109.79% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 119.2M | ↑ 18.28% |
Total Liabilities | 39.2M | ↑ 157.47% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 96.4M | ↓ 19.13% |
Total Liabilities | 38.2M | ↓ 2.42% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 117.2M | ↑ 8.47% |
Total Liabilities | 38.8M | ↑ 7.72% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 106.5M | ↓ 9.09% |
Total Liabilities | 38.5M | ↓ 0.74% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 96.4M | ↓ 9.5% |
Total Liabilities | 38.2M | ↓ 0.58% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 137.0M | ↑ 42.1% |
Total Liabilities | 58.9M | ↑ 54.09% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 122.1M | ↓ 10.83% |
Total Liabilities | 54.1M | ↓ 8.23% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -11.5M | ↑ 8.01% |
Investing Cash Flow | 6.0K | ↓ 102.74% |
Financing Cash Flow | 18.7M | ↑ 39.22% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -15.7M | ↑ 37.1% |
Investing Cash Flow | -113.0K | ↓ 1983.33% |
Financing Cash Flow | 25.2M | ↑ 34.7% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -17.7M | ↑ 12.79% |
Investing Cash Flow | -1.6M | ↑ 1335.4% |
Financing Cash Flow | 27.5M | ↑ 9.11% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -50.4M | ↑ 184.22% |
Investing Cash Flow | -8.1M | ↑ 401.48% |
Financing Cash Flow | 65.8M | ↑ 138.73% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -47.8M | ↓ 5.09% |
Investing Cash Flow | -573.0K | ↓ 92.96% |
Financing Cash Flow | 61.9M | ↓ 5.82% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -9.6M | ↑ 102.56% |
Investing Cash Flow | 4.2M | ↓ 195.8% |
Financing Cash Flow | 19.4M | ↓ 1499.42% |
Sell
Neutral
Buy
Dariohealth Corp is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Dariohealth Corp | -16.83% | -50.57% | -16.83% | -94.82% | -79.41% |
Solventum Corp | 1.89% | 11.97% | 2.32% | 2.32% | 2.32% |
Doximity, Inc. | 38.35% | 152.5% | 143.09% | -17.97% | 9.53% |
Veeva Systems Inc. | 12.4% | 16.02% | 42.27% | -25.04% | 59.48% |
Ge Healthcare Technologies Inc. | -7.31% | 4.8% | 21.3% | 40.39% | 40.39% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Dariohealth Corp | NA | NA | 0.0 | -1.03 | -0.75 | -0.35 | NA | 1.87 |
Solventum Corp | NA | NA | NA | 6.26 | 0.17 | 0.08 | NA | NA |
Doximity, Inc. | 70.4 | 70.4 | 2.42 | 0.9 | 0.19 | 0.12 | NA | 5.15 |
Veeva Systems Inc. | 63.33 | 63.33 | 1.36 | 4.76 | 0.13 | 0.06 | NA | 32.04 |
Ge Healthcare Technologies Inc. | 23.39 | 23.39 | 2.15 | 4.3 | 0.22 | 0.06 | 0.0 | 18.2 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Dariohealth Corp | Buy | $27.9M | -79.41% | NA | -205.62% |
Solventum Corp | Hold | $10.8B | 2.32% | NA | 15.73% |
Doximity, Inc. | Hold | $11.4B | 9.53% | 70.4 | 33.69% |
Veeva Systems Inc. | Buy | $38.4B | 59.48% | 63.33 | 23.91% |
Ge Healthcare Technologies Inc. | Buy | $39.0B | 40.39% | 23.39 | 8.56% |
Insights on Dariohealth Corp
Revenue is up for the last 5 quarters, 3.51M → 7.42M (in $), with an average increase of 15.9% per quarter
Netprofit is up for the last 4 quarters, -12.00M → 14.60M (in $), with an average increase of 100.6% per quarter
In the last 1 year, Doximity, Inc. has given 143.1% return, outperforming this stock by 159.9%
In the last 3 years, Dariohealth Corp has experienced a drawdown of -94.9%, however Doximity, Inc. resisted the overall trend and outperformed by 73.9%
Nantahala Capital Management, LLC
Appian WAY Asset Management
Phoenix Financial Ltd
Y.D. More Investments Ltd
Clal Insurance Enterprises Holdings Ltd
Vanguard Group Inc
DarioHealth Corp. (NASDAQ:DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric multi-chronic condition digital therapeutics platform.
Organization | Dariohealth Corp |
Employees | 276 |
CEO | Mr. Erez Raphael |
Industry | Health Technology |
Cactus Acquisition Corp 1 Ltd
$0.86
-0.22%
Rigel Resource Acquisition Corp
$0.86
-0.22%
Fortune Rise Acquisition Corp
$0.86
-0.22%
P.a.m. Transportation Svcs
$0.86
-0.22%
Onyx Acquisition Co. I
$0.86
-0.22%
Blockchain Coinvestors Acquisition Corp.
$0.86
-0.22%
Invesco S&p 500 Pure Growth Etf
$0.86
-0.22%
Grupo Aval Acciones Y Valores S.a.
$0.86
-0.22%
Sunopta Inc
$0.86
-0.22%